New data presented at the 2025 European AIDS Clinical Society (EACS) Congress suggest that a once-weekly oral regimen combining islatravir and lenacapavir could mark a major advance in HIV treatment convenience. Findings from a Phase 2 trial…
New data presented at the 2025 European AIDS Clinical Society (EACS) Congress suggest that a once-weekly oral regimen combining islatravir and lenacapavir could mark a major advance in HIV treatment convenience. Findings from a Phase 2 trial…